skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Therapeutic target for protozoal diseases

Abstract

A novel Fasciclin Related Adhesive Protein (FRAP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. FRAP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, FRAP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on FRAP, or antigenic epitopes of FRAP, either alone or in combination with other parasite antigens. Methods for the development of compounds that inhibit the catalytic activity of FRAP, and diagnostic and laboratory methods utilizing FRAP are also provided.

Inventors:
 [1];  [1];  [1]
  1. Blacksburg, VA
Publication Date:
Research Org.:
VIRGINIA POLYTECH INST/ST UNIV
Sponsoring Org.:
USDOE
OSTI Identifier:
985188
Patent Number(s):
7,438,916
Application Number:
11/249,355
Assignee:
Virginia Tech Intellectual Properties, Inc. (Blacksburg, VA)
DOE Contract Number:  
FC36-01GO11086
Resource Type:
Patent
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES

Citation Formats

Rathore, Dharmendar, Jani, Dewal, and Nagarkatti, Rana. Therapeutic target for protozoal diseases. United States: N. p., 2008. Web.
Rathore, Dharmendar, Jani, Dewal, & Nagarkatti, Rana. Therapeutic target for protozoal diseases. United States.
Rathore, Dharmendar, Jani, Dewal, and Nagarkatti, Rana. 2008. "Therapeutic target for protozoal diseases". United States. https://www.osti.gov/servlets/purl/985188.
@article{osti_985188,
title = {Therapeutic target for protozoal diseases},
author = {Rathore, Dharmendar and Jani, Dewal and Nagarkatti, Rana},
abstractNote = {A novel Fasciclin Related Adhesive Protein (FRAP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. FRAP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, FRAP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on FRAP, or antigenic epitopes of FRAP, either alone or in combination with other parasite antigens. Methods for the development of compounds that inhibit the catalytic activity of FRAP, and diagnostic and laboratory methods utilizing FRAP are also provided.},
doi = {},
url = {https://www.osti.gov/biblio/985188}, journal = {},
number = ,
volume = ,
place = {United States},
year = {Tue Oct 21 00:00:00 EDT 2008},
month = {Tue Oct 21 00:00:00 EDT 2008}
}

Works referenced in this record:

Infectivity-associated Changes in the Transcriptional Repertoire of the Malaria Parasite Sporozoite Stage
journal, August 2002